Overview

A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Perseid Therapeutics LLC
Treatments:
Abatacept